[1]聂小凤,翟慧慧,冷天艳,等.宫颈脱落细胞miR34a检测在HR-HPV阳性患者 分流中的作用分析[J].医学信息,2018,31(16):43-46.[doi:10.3969/j.issn.1006-1959.2018.16.012]
　NIE Xiao-feng,ZHAI Hui-hui,LENG Tian-yan,et al.Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients[J].Journal of Medical Information,2018,31(16):43-46.[doi:10.3969/j.issn.1006-1959.2018.16.012]
点击复制

宫颈脱落细胞miR34a检测在HR-HPV阳性患者 分流中的作用分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年16期
页码:
43-46
栏目:
论著
出版日期:
2018-08-15

文章信息/Info

Title:
Analysis of the Role of MiR34a in Cervical Exfoliated Cells in Shunt of HR-HPV Positive Patients
文章编号:
1006-1959（2018）16-0043-04
作者:
聂小凤; 翟慧慧; 冷天艳; 张 琴; 杨丽华
昆明医科大学第二附属医院妇科，云南 昆明 650101
Author(s):
NIE Xiao-feng; ZHAI Hui-hui; LENG Tian-yan; ZHANG Qin; YANG Li-hua
Department of Gynecology,Second Affiliated Hospital of Kunming Medical University,Kunming,650101,Yunnan,China
关键词:
microRNA-34a; 宫颈细胞学检查; HPV; 宫颈癌; 筛查
Keywords:
Key words：MicroRNA-34a; Cervical cytology; HPV; Cervical cancer; Screening
分类号:
R737.33
DOI:
10.3969/j.issn.1006-1959.2018.16.012
文献标志码:
A
摘要:
目的 探讨宫颈脱落细胞miR34a检测在HR-HPV阳性患者分流中的作用。方法 采用第二代杂交捕获技术（HC2）进行宫颈癌初筛，HPV阳性者行TCT及miRNA检查。TCT结果异常者（≥意义不明确的非典型鳞状细胞）阴道镜下活检行病理学检查。TCT阴性者行阴道镜检查，阴道镜异常者阴道镜下活检取材，比较不同级别宫颈病变中miR34a水平，探讨miR34a、Pap在宫颈病变中的诊断作用。结果 ①Pap对宫颈高度鳞状上皮内病变预测值的灵敏度为64.90%，特异度为80.70%，AUC为0.728（95%CI：0.657~0.779，P＜0.001）。②miRNA34a对宫颈高度鳞状上皮内病变预测值的灵敏度为77.00%，特异度为62.30%，AUC为0.824（95%CI：0.756~0.892，P＜0.001），cut off值为0.623。③miRNA34a对宫颈高度鳞状上皮内病变预测值的灵敏度高于Pap检测，特异度低于Pap。④宫颈脱落细胞miRAN34a值随着宫颈病变加重逐渐降低。结论 检测宫颈脱落细胞miR34a水平可有效分流HR-HPV阳性患者，敏感性高于Pap检查。
Abstract:
Abstract: Objective To investigate the role of miR34a in cervical exfoliated cells in the shunt of HR-HPV positive patients. Methods The second generation hybridization capture technique (HC2) was used for primary screening of cervical cancer. HPV positive patients underwent TCT and miRNA examination. Pathological examination of colposcopy biopsy was performed in patients with abnormal TCT results (≥ atypical squamous cells with unclear significance). TCT-negative patients underwent colposcopy, colposcopy biopsy was performed, and miR34a levels were compared in different grades of cervical lesions. The diagnostic role of miR34a and Pap in cervical lesions was explored. Results ① The sensitivity of 1Pap to the predictive value of high squamous intraepithelial lesion was 64.90%, the specificity was 80.70%, and the AUC was 0.728 (95% CI: 0.657~0.779, P<0.001).② The sensitivity of miRNA34a for predicting cervical high-grade squamous intraepithelial lesion was 77.00%, specificity was 62.30%, AUC was 0.824 (95% CI: 0.756~0.892, P<0.001), and cut off value was 0.623. ③The sensitivity of 3miRNA34a to the predictive value of high squamous intraepithelial lesion was higher than that of Pap, and its specificity was lower than Pap. ④ The value of miRAN34a in cervical exfoliated cells gradually decreased with the increase of cervical lesions. Conclusion Detection of miR34a levels in cervical exfoliated cells can effectively divert HR-HPV-positive patients with higher sensitivity than Pap.

参考文献/References:

[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].Ca A Cancer Journal for Clinicians,2016,66(2):115-132.
[2]Munson E,Kroeger L,Balzer S,et al.Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleicacid[J].J Clin Microbiol,2014,52(1):331-334.
[3]许剑利,徐克惠.高危型HPV检测及TCT检查在宫颈癌筛查中的应用分析[J].实用妇产科杂志,2014,30(12):946-949.
[4]Schiffman M,Wentzensen N,Wacholder S,et al.Human papillomavirus testing in the prevention of cervical cancer[J].J Natl Cancer Inst,2011,103(5):368-383.
[5]陈娇,孔为民.宫颈癌筛查方案研究进展[J].中国医药导报,2015,12(14):27-30,49.
[6]王宝晨,薛凤霞.《2015年美国宫颈癌筛查过渡期临床指南》解读[J].国际生殖健康/计划生育杂志,2015,34(06):495-498.
[7]De Sanjosé S,Diaz M,Castellsagué X,et al.Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:a meta-analysis[J].Lancet Infect Dis,2007,7(7):453-459.
[8]Lui R.Clinical utility of HPV testing[J].Clinical Obstetrics and Gynecology,2013,56(1):17-24.
[9]郭金满,胡火军,谭园.微小RNA检测方法在临床诊断中应用的研究进展[J].广东医学,2015,36(05):809-811.
[10]Hermeking H.MicroRNAs in the p53 network:micromanagement of tumour suppression[J].Nat Rev Cancer,2012,12(9):613-626.
[11]沈丹华,陈定宝.解读第4版WHO女性生殖器官肿瘤分类中的变化[J].中华妇产科杂志,2014,49(9):717-720.
[12]Franceschi S,Denny L,Irwin KL,et al.EUROGIN 2010 roadmap on cervical cancer prevention[J].Int J Cancer,2011,128(12):2765-2774.
[13]Whitlock EP,Vesco KK,Eder M,et al.Liquid-based cytology and human papollomavirus testing to screen for cervical cancer:a systematic review for the US. Preventive Services Task Force[J].Ann Intern Med,2011,155(10):687-697.
[14]Wright TC,Stoler MH,Behrens CM,et al.Interlaboratory variation in the performance of liquid0based cytology:insights from the Athena trial[J].Int J Cancer,2014,134(8):1835-1843.
[15]Pritchard CC,Cheng HH,Tewari M.MicroRNA profiling:approaches and considerations[J].Nat Rev Genet,2012,13(5):358-369.
[16]Zheng ZM,Wang X.Regulation of cellular miRNA expression by human papillomaviruses[J].Biochim Biophys Acta,2011,1809(11-12):668-677.
[17]Krol J,Loedige I,Filipowicz W.The widespread regulation of microRNA biogenesis,function and decay[J].Nat Rev Genet,2010,11(9):597-610.
[18]Hermeking H.MicroRNAs in the p53 network:micromanagement of tumour suppression[J].Nat Rev Cancer,2012,12(9):613-626.
[19]Li B.Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection[J].Int J Gynecol Cancer,2010,20(4):597-604.

更新日期/Last Update: 2018-08-15